Irving Sally
Tissue Viability Service Manager at Somerset Partnership NHS Trust, at the time of the study now, Independent Tissue Viability Nurse Consultant at Specialist Wound Care (Boocare Ltd).
Br J Community Nurs. 2019 Sep 1;24(Sup9):S33-S37. doi: 10.12968/bjcn.2019.24.Sup9.S33.
One of the biggest challenges faced by healthcare providers is the treatment of chronic, non-healing wounds. This paper reports for the first time in the UK the results of five case studies in which a novel regenerating matrix-based therapy, CACIPLIQ20, was used. CACIPLIQ20 is a heparan sulphate mimetic designed to replace the destroyed heparan sulphate in the extracellular matrix of wound cells. All five patients in this case series had chronic, non-healing ulcers that had not improved with conventional care. Treatment included two applications of CACIPLIQ20 per week, for a maximum of 12 weeks. Three of the five wounds healed completely, and the remaining two showed significant improvements in size and quality. The treatment was well tolerated by the patients and also led to a significant reduction in pain. Moreover, CACIPLIQ20 treatment was found to be highly cost-effective when compared to conventional care, with the potential to save healthcare systems significant resources. Further studies are needed to build a strong evidence base on the use of this product, but these preliminary findings are certainly promising.
医疗服务提供者面临的最大挑战之一是慢性难愈合伤口的治疗。本文首次在英国报告了五项案例研究的结果，这些研究使用了一种新型的基于再生基质的疗法——CACIPLIQ20。CACIPLIQ20是一种硫酸乙酰肝素模拟物，旨在替代伤口细胞外基质中被破坏的硫酸乙酰肝素。该案例系列中的所有五名患者都患有慢性难愈合溃疡，常规治疗均未见好转。治疗方法为每周应用两次CACIPLIQ20，最长持续12周。五个伤口中有三个完全愈合，其余两个在大小和质量上有显著改善。患者对该治疗耐受性良好，疼痛也显著减轻。此外，与传统治疗相比，发现CACIPLIQ20治疗具有很高的成本效益，有可能为医疗系统节省大量资源。需要进一步开展研究以建立关于该产品使用的强有力证据基础，但这些初步发现肯定很有前景。
